# Simris Group > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/simrisgroup). ## Overview Simris Group is a Swedish biologics company focused on identifying and commercialising natural bioactive compounds from microalgae and cyanobacteria. Its work spans discovery, extraction and development of compounds for use in biopharmaceuticals, dietary supplements and cosmetics, with shares listed on Nasdaq First North Growth Market in Sweden. ## Products & services • Microalgae- and cyanobacteria-derived bioactive compounds • ADC payload candidates based on microcystins • Biopharmaceutical research and development programs • Dietary supplement ingredients and products • Cosmetic ingredient applications - **Biopharma payloads** (45%) — Natural compounds and payload candidates developed for antibody-drug conjugates and oncology applications. - **Dietary supplements** (25%) — Omega-3 and other supplement products and ingredients sold through distributors and direct channels. - **Cosmetic ingredients** (10%) — Bioactive natural ingredients intended for use in cosmetic formulations. - **Research and development services** (20%) — Preclinical studies, screening and development work around proprietary cyanobacterial compounds. - Microalgae- and cyanobacteria-derived bioactive compounds - ADC payload candidates based on microcystins - Biopharmaceutical research and development programs - Dietary supplement ingredients and products - Cosmetic ingredient applications ## Customers Simris Group serves pharmaceutical and biotech counterparties interested in novel payloads for targeted cancer therapies, especially ADC developers and research partners. It also addresses consumer-facing and ingredient markets through dietary supplement and cosmetic applications, where buyers seek natural, differentiated bioactive inputs. The customer base therefore spans early-stage biopharma collaborators, ingredient buyers and end-market distributors. - **Biopharmaceutical partners** (primary) — Buy or evaluate ADC payload candidates and preclinical data for oncology programs. - **Research organizations and CROs** (primary) — Support in vitro and in vivo studies of proprietary compounds and payload platforms. - **Supplement distributors** (secondary) — Purchase omega-3 supplement products for resale through retail and online channels. - **Cosmetics ingredient buyers** (secondary) — Source natural bioactive ingredients for formulation into cosmetic products. - Biopharma companies developing ADCs and targeted oncology therapies - Research organizations running preclinical screening and validation studies - Supplement distributors and retailers buying omega-3 products - Cosmetic formulators seeking natural bioactive ingredients - Potential licensing or collaboration partners for proprietary compounds ## Geography Simris Group is headquartered in Sweden and is listed on Nasdaq First North Growth Market in Stockholm. Its reported activity is international in nature, with European research partners and prospective counterparties mentioned in the reports, and with the Hammenhög production asset in Sweden forming part of the operational base. The business is exposed to cross-border collaboration, regulatory requirements and supply-chain execution across Europe and beyond. - Sweden is the corporate and operational base - Nasdaq First North Growth Market is the listing venue - European partners are important for research and collaboration - Hammenhög is the main production asset referenced in reports - International business development broadens market reach ## Strategy Simris Group is concentrating on proprietary cyanobacteria-derived payloads for antibody-drug conjugates and related oncology applications. The company is also evaluating the future of its production assets and has reduced emphasis on lower-value consumer supplement activity, aiming to focus resources on higher-value scientific programs and partnership opportunities. - **Advance ADC payload development** (short-term) — Proprietary payload science is the core value driver and differentiator. - **Secure partnerships and validation** (short-term) — External validation and collaboration are needed to convert science into commercial value. - **Optimize asset footprint** (medium-term) — The production asset base must align with capital availability and strategic focus. - Advance proprietary microcystin payload platform for ADCs - Generate preclinical data to support partnering discussions - Build collaborations with CROs and biopharma counterparties - Evaluate strategic options for the Hammenhög production asset - De-emphasize lower-priority supplement activities ## Risks Simris Group faces the typical risks of an early-stage biotech company: scientific uncertainty, long development timelines and dependence on external funding. Its legacy supplement and production activities also expose it to execution risk, while any partnership or asset-sale process can be delayed or fail to close on acceptable terms. - **External funding dependence** [critical] — The company is in a start-up phase and relies on new capital to continue operations and growth plans. - **Scientific and development risk** [high] — ADC payload programs depend on preclinical results, technical validation and eventual partner interest. - **Asset divestment execution risk** [medium] — The Hammenhög sale process may take time, fail, or close below expectations. - **Commercialization risk in supplements** [medium] — Consumer supplement sales have been de-emphasized and may not provide meaningful scale. - Funding dependence creates dilution and liquidity risk - Preclinical programs may fail to translate into commercial products - Partnering timelines can be long and outcomes uncertain - Asset divestment may not complete on expected terms - Small scale increases operational and execution risk ## Accounting Simris Group reports under Swedish K3 rules, so investors should watch how development costs, asset values and related-party financing are treated. The business also has judgment-heavy areas around impairment or disposal accounting for production assets, conversion features in shareholder loans, and the timing of any revenue from small-scale product sales or collaborations. - **Development cost treatment** — Reported operating result and intangible assets - **Asset impairment and disposal** — Balance sheet carrying values and gain/loss on disposal - **Convertible related-party loans** — Liabilities, finance costs and share count - **Related-party disclosures** — Governance and note transparency - Capitalization versus expensing of development work affects reported loss - Impairment or disposal accounting may affect Hammenhög asset values - Convertible related-party loans affect debt and equity presentation - Small revenue base makes timing of collaboration income important - Related-party services and loans require careful disclosure --- *Last updated: 2026-08-11T04:04:55.777234+00:00*